Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale School of Medicine
New Haven, Connecticut, United States
- Florida Cancer Specialists-South
Fort Myers, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Woodlands Medical Center
Pensacola, Florida, United States
- Florida Cancer Specialists-North
St. Petersburg, Florida, United States
- Research Medical Center
Kansas City, Missouri, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2011
- Primary completion
- 28 Feb 2015
- Completion
- 28 Feb 2015
- Last update posted
- 4 Oct 2016
- Registered enrollment
- 25
- Registry id
- NCT01404650
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.